Shinpoong Pharmaceutical Co.,Ltd (KRX:019170)
South Korea
· Delayed Price · Currency is KRW 10,910
-310 (-2.76%)
At close: Jun 5, 2025, 3:30 PM KST
KRX:019170 Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | -14,074 | -15,387 | -57,325 | -35,377 | -11,584 | 5,003 | Upgrade
|
| Depreciation & Amortization | 11,772 | 11,963 | 11,908 | 12,803 | 12,675 | 12,208 | Upgrade
|
| Loss (Gain) From Sale of Assets | -6.89 | -6.89 | -39.65 | -18.31 | -49.02 | 29.96 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | - | 703.23 | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -1,307 | -1,216 | 1,011 | -845.62 | -253.64 | 868.38 | Upgrade
|
| Loss (Gain) on Equity Investments | - | - | 6,514 | 697.09 | -2,620 | -2,520 | Upgrade
|
| Provision & Write-off of Bad Debts | -1,589 | -86.42 | 2,939 | 1,395 | -937.06 | 621.88 | Upgrade
|
| Other Operating Activities | 244.39 | -588.5 | 9,834 | 6,692 | -58,525 | 9,727 | Upgrade
|
| Change in Accounts Receivable | 4,766 | 3,090 | 5,805 | -1,225 | 8,199 | 9,298 | Upgrade
|
| Change in Inventory | 1,742 | -942.29 | -7,049 | 972.41 | 1,774 | -248.1 | Upgrade
|
| Change in Accounts Payable | -4,339 | 209.57 | -2,295 | -435.91 | 3,385 | -9,525 | Upgrade
|
| Change in Other Net Operating Assets | -12,127 | -12,190 | 3,890 | -11,806 | -23,093 | -5,401 | Upgrade
|
| Operating Cash Flow | -14,919 | -15,155 | -24,808 | -26,444 | -71,028 | 20,062 | Upgrade
|
| Operating Cash Flow Growth | - | - | - | - | - | 3.68% | Upgrade
|
| Capital Expenditures | -4,367 | -5,569 | -14,888 | -5,323 | -4,425 | -2,654 | Upgrade
|
| Sale of Property, Plant & Equipment | 6.9 | 6.9 | 53.26 | 1.01 | 16.63 | 16.09 | Upgrade
|
| Sale (Purchase) of Intangibles | -528.34 | -519.7 | -142.52 | -334.9 | -953.63 | -338.43 | Upgrade
|
| Investment in Securities | -3,122 | 2,523 | -1,182 | 48,846 | 54,379 | -92,080 | Upgrade
|
| Other Investing Activities | 9,142 | 9,142 | -150 | 8.01 | 11.16 | 99.89 | Upgrade
|
| Investing Cash Flow | 1,130 | 5,583 | -16,309 | 43,197 | 49,028 | -94,957 | Upgrade
|
| Long-Term Debt Issued | - | 12,000 | 45,000 | - | 10,000 | 26,943 | Upgrade
|
| Long-Term Debt Repaid | - | -5,843 | -1,761 | -1,869 | -11,262 | -133,644 | Upgrade
|
| Net Debt Issued (Repaid) | 5,235 | 6,157 | 43,239 | -1,869 | -1,262 | -106,701 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | - | 215,355 | Upgrade
|
| Common Dividends Paid | - | - | - | - | -5,156 | - | Upgrade
|
| Other Financing Activities | 40 | 40 | -40 | - | - | -0 | Upgrade
|
| Financing Cash Flow | 5,275 | 6,197 | 43,199 | -1,869 | -6,418 | 108,654 | Upgrade
|
| Foreign Exchange Rate Adjustments | 2,387 | 1,561 | 27.29 | -830.79 | 252.16 | -1,331 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | 0 | 0 | -0 | -0 | 0 | - | Upgrade
|
| Net Cash Flow | -6,126 | -1,814 | 2,109 | 14,054 | -28,166 | 32,428 | Upgrade
|
| Free Cash Flow | -19,286 | -20,724 | -39,696 | -31,767 | -75,453 | 17,408 | Upgrade
|
| Free Cash Flow Growth | - | - | - | - | - | 139.24% | Upgrade
|
| Free Cash Flow Margin | -8.67% | -9.37% | -19.82% | -15.18% | -39.87% | 8.80% | Upgrade
|
| Free Cash Flow Per Share | -379.06 | -404.27 | -774.37 | -619.69 | -1471.90 | 345.89 | Upgrade
|
| Cash Interest Paid | 2,642 | 2,566 | 1,647 | 2.06 | 158.16 | 3,107 | Upgrade
|
| Cash Income Tax Paid | 3,528 | 3,312 | -2,962 | -554.25 | 65,648 | 472.25 | Upgrade
|
| Levered Free Cash Flow | -2,238 | -5,184 | -26,774 | -16,386 | -48,674 | 70,074 | Upgrade
|
| Unlevered Free Cash Flow | -556.97 | -3,539 | -25,700 | -16,348 | -48,548 | 71,915 | Upgrade
|
| Change in Net Working Capital | -2,148 | -1,229 | -7,043 | 2,232 | 46,903 | -57,858 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.